Pembrolizumab ‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer

Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication. AbstractTumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication.

Source: Clinical Case Reports - February 15, 2020 Category: General Medicine Authors: Manan Shah, Sanjay Jain, Temidayo Abe, Phani Keerthi Surapaneni, Kapil Bhatia Tags: CASE REPORT Source Type: research